Eric Benevich Sells 19,818 Shares of Neurocrine Biosciences, Inc. (NASDAQ:NBIX) Stock

Neurocrine Biosciences, Inc. (NASDAQ:NBIX - Get Free Report) insider Eric Benevich sold 19,818 shares of the company's stock in a transaction dated Monday, April 15th. The stock was sold at an average price of $133.36, for a total value of $2,642,928.48. Following the completion of the sale, the insider now owns 40,778 shares in the company, valued at approximately $5,438,154.08. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink.

Eric Benevich also recently made the following trade(s):

• On Thursday, March 14th, Eric Benevich sold 75,000 shares of Neurocrine Biosciences stock. The stock was sold at an average price of $139.38, for a total value of $10,453,500.00.

Neurocrine Biosciences Price Performance

Neurocrine Biosciences stock traded up $0.24 during trading on Wednesday, reaching $133.23. 571,073 shares of the company were exchanged, compared to its average volume of 851,005. Neurocrine Biosciences, Inc. has a 52-week low of $89.04 and a 52-week high of $148.37. The company has a market capitalization of $13.26 billion, a P/E ratio of 55.45 and a beta of 0.25. The stock's 50 day simple moving average is $136.25 and its two-hundred day simple moving average is $126.77.

Neurocrine Biosciences (NASDAQ:NBIX - Get Free Report) last posted its earnings results on Wednesday, February 7th. The company reported $1.44 EPS for the quarter, beating analysts' consensus estimates of $1.13 by $0.31. Neurocrine Biosciences had a return on equity of 12.85% and a net margin of 13.23%. The company had revenue of $515.20 million for the quarter, compared to the consensus estimate of $518.52 million. During the same quarter in the previous year, the business earned $0.88 earnings per share. The company's revenue for the quarter was up 25.0% on a year-over-year basis. As a group, equities analysts forecast that Neurocrine Biosciences, Inc. will post 4.84 earnings per share for the current year.

Wall Street Analysts Forecast Growth

NBIX has been the topic of a number of recent analyst reports. Barclays increased their price target on Neurocrine Biosciences from $145.00 to $150.00 and gave the stock an "overweight" rating in a research report on Tuesday, January 23rd. StockNews.com upgraded Neurocrine Biosciences from a "buy" rating to a "strong-buy" rating in a research report on Thursday, February 8th. JPMorgan Chase & Co. increased their price target on Neurocrine Biosciences from $148.00 to $158.00 and gave the stock an "overweight" rating in a research report on Wednesday, March 20th. Wells Fargo & Company increased their price target on Neurocrine Biosciences from $127.00 to $140.00 and gave the stock an "equal weight" rating in a research report on Thursday, February 8th. Finally, Citigroup decreased their target price on Neurocrine Biosciences from $141.00 to $140.00 and set a "neutral" rating on the stock in a research report on Thursday, February 8th. Six equities research analysts have rated the stock with a hold rating, sixteen have given a buy rating and one has issued a strong buy rating to the company's stock. Based on data from MarketBeat.com, Neurocrine Biosciences currently has an average rating of "Moderate Buy" and an average target price of $139.67.

Institutional Investors Weigh In On Neurocrine Biosciences

A number of institutional investors and hedge funds have recently added to or reduced their stakes in NBIX. Hennion & Walsh Asset Management Inc. raised its holdings in shares of Neurocrine Biosciences by 14.3% in the 1st quarter. Hennion & Walsh Asset Management Inc. now owns 6,805 shares of the company's stock valued at $939,000 after buying an additional 853 shares during the period. Toth Financial Advisory Corp raised its holdings in shares of Neurocrine Biosciences by 34.6% in the 1st quarter. Toth Financial Advisory Corp now owns 5,500 shares of the company's stock valued at $759,000 after buying an additional 1,413 shares during the period. Chesley Taft & Associates LLC purchased a new stake in shares of Neurocrine Biosciences in the 1st quarter valued at $1,034,000. Wealth Enhancement Advisory Services LLC raised its holdings in shares of Neurocrine Biosciences by 48.5% in the 1st quarter. Wealth Enhancement Advisory Services LLC now owns 4,744 shares of the company's stock valued at $654,000 after buying an additional 1,550 shares during the period. Finally, Park Avenue Securities LLC raised its holdings in shares of Neurocrine Biosciences by 1.1% in the 1st quarter. Park Avenue Securities LLC now owns 9,570 shares of the company's stock valued at $1,320,000 after buying an additional 101 shares during the period. Hedge funds and other institutional investors own 92.59% of the company's stock.

About Neurocrine Biosciences

Neurocrine Biosciences, Inc discovers, develops, and markets pharmaceuticals for neurological, neuroendocrine, and neuropsychiatric disorders in the United States and internationally. The company's products include INGREZZA for tardive dyskinesia and chorea associated with Huntington's disease; ALKINDI for adrenal insufficiency; Efmody capsules for classic congenital adrenal hyperplasia; Orilissa tablets for endometriosis; and Oriahnn capsules to treat uterine fibroids.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.